Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Xuhua Xu
CONTACT
Lead
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Background: Lecanemab is an antibody used for the treatment of Alzheimer's disease (AD). Monitoring its therapeutic efficacy accurately is crucial for patient management. Traditional methods can be complex or less sensitive. This study introduces a highly sensitive electrochemiluminescence (ECL) assay using mesoporous gold electrodes to detect AD-related plasma biomarkers. Study Design: This is an observational/clinical study involving patients diagnosed with Alzheimer's disease who are receiving Lecanemab treatment. Methodology: Blood samples will be collected from participants at scheduled visits. The levels of specific AD biomarkers in the plasma will be measured using the developed mesoporous gold electrode ECL system. These measurements will be correlated with clinical outcomes to assess the drug's efficacy. The study also aims to establish the reliability and sensitivity of this specific ECL technique for routine clinical monitoring.
Age
50–90
Sex
ALL
Healthy volunteers
Not accepted